Form 4 for PHIO Phio Pharmaceuticals Corp.
Accepted 2025-09-15 00:00:00 ET · period of report 2025-09-11 · accession 0001683168-25-006954 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-15 | 2025-09-11 | PHIO | Bitterman Robert J | COB, Pres, CEO, Dir | F - Tax | $2.32 | -4,111 | 21.4K | -16% | -$9,538 | |
| 2025-09-15 | 2025-09-11 | PHIO | Bitterman Robert J | COB, Pres, CEO, Dir | A - Grant | $0.00 | +250.0K | 271.4K | +1,167% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $.0001 par value | 2025-09-11 | F | D | 4,111 | $2.32 | 21,421 | D | — | — | |
| 2 | Common | Common Stock, $.0001 par value | 2025-09-11 | A | A | 250,000 | $0.00 | 271,421 | D | — | — | (F2) Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. (F3) Includes shares of common stock underlying unvested restricted stock units. |